{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:29:56Z","timestamp":1790886596050,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40265-013-0064-9","type":"journal-article","created":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T09:43:10Z","timestamp":1369993390000},"page":"979-988","source":"Crossref","is-referenced-by-count":70,"title":["Canagliflozin: First Global Approval"],"prefix":"10.1007","volume":"73","author":[{"given":"Shelley","family":"Elkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,1]]},"reference":[{"issue":"1","key":"64_CR1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2337\/diaspect.25.1.29","volume":"25","author":"B Dokken","year":"2012","unstructured":"Dokken B. The kidney as a treatment target for type 2 diabetes. Diabetes Spectr. 2012;25(1):29\u201336.","journal-title":"Diabetes Spectr"},{"issue":"2","key":"64_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tips.2010.11.011","volume":"32","author":"CJ Bailey","year":"2011","unstructured":"Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32(2):63\u201371.","journal-title":"Trends Pharmacol Sci"},{"key":"64_CR3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JM, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364\u201379.","journal-title":"Diabetes Care"},{"issue":"4","key":"64_CR4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318680-000000000-00000","volume":"70","author":"JJ Neumiller","year":"2010","unstructured":"Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377\u201385.","journal-title":"Drugs"},{"key":"64_CR5","unstructured":"Janssen Pharmaceuticals Inc. Invokana\u2122 (canagliflozin) tablets, for oral use: US prescribing information. 2013. http:\/\/www.janssenmd.com\/pdf\/invokana\/PI-INVOKANA.pdf . Accessed 19 Apr 2013."},{"key":"64_CR6","unstructured":"European Medicines Agency. Forxiga (dapagliflozin): summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002322\/WC500136026.pdf . Accessed 6 May 2013."},{"key":"64_CR7","unstructured":"Janssen Pharmaceuticals Inc. U.S. FDA approves canagliflozin (TA-7284) for the treatment of adult patients with type 2 diabetes. 2013. http:\/\/www.tanabe.co.jp . Accessed 5 Apr 2013."},{"key":"64_CR8","unstructured":"European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use: April 2013. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2013\/04\/WC500142012.pdf . Accessed 19 Apr 2013."},{"key":"64_CR9","unstructured":"Janssen Research and Development LLC. Janssen Research and Development submits New Drug Application to U.S. FDA for canagliflozin to treat patients with type 2 diabetes. 2012. http:\/\/www.janssenrnd.com . Accessed 5 Apr 2013."},{"key":"64_CR10","unstructured":"Johnson and Johnson. A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and efficacy of JNJ-28431754 in nondiabetic overweight and obese subjects [ClinicalTrials.gov identifier NCT00650806]. US National Institutes of Health, ClinicalTrials.gov. 2012. http:\/\/www.clinicaltrials.gov . Accessed 15 Apr 2013."},{"key":"64_CR11","unstructured":"Janssen Research and Development LLC. FDA Advisory Committee recommends approval of canagliflozin for treatment of adults with type 2 diabetes. 2013. http:\/\/www.janssenrnd.com . Accessed 5 Apr 2013."},{"key":"64_CR12","unstructured":"Janssen Pharmaceuticals Inc. Canagliflozin Advisory Committee Meeting: Endocrinologic and Metabolic Drugs Advisory Committee. 2013. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM336236.pdf . Accessed 6 May 2013."},{"key":"64_CR13","unstructured":"Janssen-Cilag International NV. Janssen submits European Marketing Authorisation Application for canagliflozin in type 2 diabetes. 2012. http:\/\/www.janssen-emea.com . Accessed 5 Apr 2013."},{"key":"64_CR14","unstructured":"Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co. Ltd. Daiichi Sankyo and Mitsubishi Tanabe Pharma establish strategic alliance to contribute to the treatment of diabetes in Japan. 2012. http:\/\/www.daiichisankyo.com . Accessed 5 Apr 2013."},{"key":"64_CR15","unstructured":"Mitsubishi Tanabe Pharma Corporation. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of TA-7284 as monotherapy in the treatment of subjects with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT01413204]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov . Accessed 5 Apr 2013."},{"issue":"Suppl","key":"64_CR16","first-page":"A274","volume":"60","author":"N Inagaki","year":"2011","unstructured":"Inagaki N, Kondo K, Iwasaki T, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM) [abstract no. 999-P]. Diabetes. 2011;60(Suppl):A274.","journal-title":"Diabetes"},{"key":"64_CR17","unstructured":"Mitsubishi Tanabe Pharma Corporation. A randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-ranging study in subjects with type 2 diabetes mellitus to evaluate the efficacy, safety and tolerability of orally administered SGLT2 inhibitorTA-7284 [ClinicalTrials.gov identifier NCT01022112]. US National Institutes of Health, ClinicalTrials.gov. 2010. http:\/\/www.clinicaltrials.gov . Accessed 5 Apr 2013."},{"key":"64_CR18","unstructured":"Mitsubishi Tanabe Pharma Corporation. An open-label, multicenter study to evaluate the long-term safety, tolerability and efficacy of TA-7284 in subjects with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT01387737]. US National Institutes of Health, ClinicalTrials.gov. 2010. http:\/\/www.clinicaltrials.gov . Accessed 5 Apr 2013."},{"key":"64_CR19","unstructured":"Mitsubishi Tanabe Pharma Corporation. Establishment of Mitsubishi Tanabe Pharma Corporation. 2007. http:\/\/www.mt-pharma.co.jp . Accessed 5 Apr 2013."},{"issue":"2","key":"64_CR20","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7(2):e30555.","journal-title":"PLoS One"},{"issue":"Suppl.1","key":"64_CR21","first-page":"S108","volume":"55","author":"S Mudaliar","year":"2012","unstructured":"Mudaliar S, Ciaraldi TP, Sha S, et al. Canagliflozin lowers postprandial plasma glucose and insulin excursions by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion [abstract no. 244]. Diabetologia. 2012;55(Suppl.1):S108\u20139.","journal-title":"Diabetologia"},{"issue":"7","key":"64_CR22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","volume":"13","author":"S Sha","year":"2011","unstructured":"Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669\u201372.","journal-title":"Diabetes Obes Metab"},{"key":"64_CR23","unstructured":"Sarich T, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, increases 24-hour urinary glucose excretion and reduces body weight in obese subjects over 2\u00a0weeks of treatment [abstract no. 874]. 46th Annual Meeting of the European Association for the Study of Diabetes; 20\u201324 Sep 2010; Stockholm."},{"issue":"Suppl","key":"64_CR24","first-page":"A294","volume":"60","author":"D Polidori","year":"2011","unstructured":"Polidori D, Sakai M, Devineni D. Exposure-response modeling of canagliflozin effects on the renal glucose threshold in subjects with type 2 diabetes (T2DM) [abstract no. 1072-P]. Diabetes. 2011;60(Suppl):A294.","journal-title":"Diabetes"},{"issue":"6","key":"64_CR25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","volume":"14","author":"D Devineni","year":"2012","unstructured":"Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28\u00a0days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539\u201345.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl","key":"64_CR26","first-page":"A24","volume":"61","author":"PP Stein","year":"2012","unstructured":"Stein PP, Berg JK, Morrow L, et al. Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes mellitus (T2DM) by a non-renal mechanism [abstract no. 84-OR]. Diabetes. 2012;61(Suppl):A24.","journal-title":"Diabetes"},{"key":"64_CR27","unstructured":"Polidori D, Zhao Y, Sha S. Canagliflozin treatment improves beta cell function in subjects with type 2 diabetes [abstract no. 646-P]. 70th Annual Scientific Sessions of the American Diabetes Association; 25\u201329 Jun 2010; Orlando (FL)."},{"key":"64_CR28","unstructured":"Wexler D, Vandebosch AN, Usiskin K, et al. Study of electrocardiogram intervals in healthy adults receiving single oral doses of canagliflozin [abstract no. 2177-PO]. 70th Annual Scientific Sessions of the American Diabetes Association; 25\u201329 Jun 2010; Orlando (FL)."},{"issue":"Suppl","key":"64_CR29","first-page":"S98","volume":"91","author":"D Devineni","year":"2012","unstructured":"Devineni D, Curtin CR, Polidori D, et al. Canagliflozin, a sodium glucose co-transporter 2 [SGLT2] inhibitor: pharmacokinetics (PK) and pharmacodynamics (PD) in subjects with type 2 diabetes mellitus (T2DM) [abstract]. Clin Pharmacol Ther. 2012;91(Suppl):S98.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"64_CR30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenlof","year":"2013","unstructured":"Stenlof K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372\u201382.","journal-title":"Diabetes Obes Metab"},{"key":"64_CR31","unstructured":"Janssen Research and Development LLC. A randomized, double-blind, placebo and active comparator-controlled, 4-arm, parallel group, multicenter study to evaluate the efficacy, safety, and tolerability of canagliflozin in the treatment of subjects with type 2 diabetes mellitus with inadequate glycaemic control on metformin monotherapy [ClinicalTrials.gov identifier NCT01106677]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov . Accessed 22 Apr 2013."},{"issue":"Suppl.1","key":"64_CR32","first-page":"S314","volume":"55","author":"L Niskanen","year":"2012","unstructured":"Niskanen L, Cefalu WT, Leiter LA, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [abstract no. 763]. Diabetologia. 2012;55(Suppl.1):S314.","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"64_CR33","first-page":"S315","volume":"55","author":"J Wilding","year":"2012","unstructured":"Wilding J, Mathieu C, Deng L, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea [abstract no. 766]. Diabetologia. 2012;55(Suppl.1):S315\u20136.","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"64_CR34","first-page":"S313","volume":"55","author":"D Polidori","year":"2012","unstructured":"Polidori D, Vercruysse F, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves indices of beta cell function in patients with type 2 diabetes on metformin plus sulphonylurea [abstract no. 761]. Diabetologia. 2012;55(Suppl.1):S313.","journal-title":"Diabetologia"},{"key":"64_CR35","unstructured":"Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycaemic control with metformin plus a sulfonylurea. Diabetes Care. 2013. doi: 10.2337\/dc12-491\/-\/DCI ."},{"key":"64_CR36","unstructured":"Guthrie R, Goldenberg R, Vijapurkar U, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus on metformin and pioglitazone [abstract]. 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension; 8\u201311 Nov 2012; Barcelona."},{"issue":"Suppl.1","key":"64_CR37","first-page":"S314","volume":"55","author":"DR Matthews","year":"2012","unstructured":"Matthews, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +\/\u2212 oral agents in type 2 diabetes [abstract no. 764]. Diabetologia. 2012;55(Suppl.1):S314\u20135.","journal-title":"Diabetologia"},{"key":"64_CR38","unstructured":"Janssen Pharmaceuticals Inc. A efficacy, safety, and tolerability study of canagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin alone or in combination with a sulfonylurea [ClinicalTrials.gov identifier NCT01381900]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov . Accessed 22 Apr."},{"issue":"6","key":"64_CR39","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232\u20138.","journal-title":"Diabetes Care"},{"issue":"Suppl.1","key":"64_CR40","first-page":"S315","volume":"55","author":"B Bode","year":"2012","unstructured":"Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin (CANA), a sodium glucose cotransporter 2 inhibitor (SGLT2), in older subjects with type 2 diabetes mellitus [abstract no. 765]. Diabetologia. 2012;55(Suppl.1):S315.","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"64_CR41","first-page":"S312","volume":"55","author":"JF Yale","year":"2012","unstructured":"Yale JF, Bakris G, Wajs E, et al. Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves glycaemic control and is well tolerated in type 2 diabetes mellitus (T2DM) subjects with moderate renal impairment [abstract no. 759]. Diabetologia. 2012;55(Suppl.1):S312.","journal-title":"Diabetologia"},{"key":"64_CR42","unstructured":"Janssen Research and Development LLC. A safety and efficacy study of canagliflozin in older patients (55 to 80\u00a0years of age) with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT01106651]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov . Accessed 22 Apr."},{"key":"64_CR43","unstructured":"Janssen Research and Development LLC. CANVAS: CANagliflozin cardioVascular Assessment Study [ClinicalTrials.gov identifier NCT01032629]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov . Accessed 22 Apr 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0064-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0064-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0064-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:31Z","timestamp":1559490091000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0064-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["64"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0064-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}